Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.
Abstract
AIM: High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo. OBJECTIVE: To investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA). DESIGN AND SETTING: A prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and 3 (2-5) weeks after the last study infusion. PATIENTS: Five hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively. INTERVENTION: Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001. MAIN OUTCOME MEASURES: The primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent atheroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints. RESULTS: The nominal change in the total atheroma volume (adjusted means) was -2.71, -3.13, -1.50, and -3.05 mm(3) with placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P = 0.81). There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, -0.02, 0.01, and 0.19%; nominal P = 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was -0.022, -0.036, -0.022, and -0.015 mm (nominal P = 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score was -0.51, 2.65, 0.71, and -0.77% (compared with placebo, nominal P = 0.85 for 12 mg/kg and nominal P = 0.01 for 3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and 12 (9.8%) in the four groups. CONCLUSION: CER-001 infusions did not reduce coronary atherosclerosis on IVUS and QCA when compared with placebo. Whether CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await further study. Name of the trial registry: Clinicaltrials.gov; Registry's URL: http://clinicaltrials.gov/ct2/show/NCT01201837?term=cer-001&rank=2; TRIAL REGISTRATION NUMBER: NCT01201837.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, several randomized trials have shown that directly infused HDL mimetics increase plasma HDL-C concentrations, but do not reduce the progression of atherosclerosis as measured by intravascular ultrasound [68,69].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
The State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors
Murray, C. J. L. (2013) · JAMA · doi:10.1001/jama.2013.13805 · Cited by 2,438
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Self-citationTardif, J.-C. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 726
Self-citationHPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Probucol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty
Tardif, J.-C., Côté, G., Lespérance, J., Bourassa, M., Lambert, J., Doucet, S., Bilodeau, L., Nattel, S., & de Guise, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370601 · Cited by 565
Self-citationWaters, D., Higginson, L., Gladstone, P., Kimball, B., Le May, M., Boccuzzi, S. J., & Lespérance, J. (1994) · Circulation · doi:10.1161/01.cir.89.3.959 · Cited by 499 · cited 1×
“20,21 Quantitativecoronaryangiographywasperformedbyexperiencedtech-nicians supervised by an expert physician in matched projections from baseline and follow-up angiograms.”
Self-citation
Research works printed but not linked: 1
- Keyserling, 2011, Circulation, 124, A15525
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Cholesterol, inflammation and innate immunity.
Tall, A. R., & Yvan-Charvet, L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3793 · Cited by 1,479
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870
Mechanisms of foam cell formation in atherosclerosis
Chistiakov, D. A., Melnichenko, A. A., Myasoedova, V. A., Grechko, A. V., & Orekhov, A. N. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1575-8 · Cited by 742
Metadata
- Authors
- Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., L'Allier, P. L., Lesperance, J., Luscher, T. F., Paolini, J. F., Tawakol, A., Waters, D. D., for the Can Hdl Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators, Pfeffer, M., Brown, V., Rouleau, J., Watkins, P., Wei, L. J., Gosselin, G., Chayer, C., Lanthier, S., Pelletier, G. B., Racine, N., Agarwal, H., Brilakis, E., Cannon, L., Carrie, D., Corbelli, J., Coste, P., de Winter, R., Diaz, A., Eisenberg, S., Ennis, B., Fajadet, J., Fam, N., Fortuin, D., Gessler, C., Grines, C., Guerra, D., Gum, H., Haldis, T., Heestermans, T., Herrman, J. P., Huynh, T., Kedhi, E., Koren, M., Kouz, S., Krolick, M., Kumkumian, G., Lavi, S., Li, R. J., Masud, A., McAlhany, C., McGrew, F. A., O'Shaughnessy, C., Oude Ophuis, A. J. M., Parr, K., Penny, W., Pesant, Y., Post, H., Robinson, S., Rodes-Cabau, J., Roy, A., Schulman, S., Spence, F., Stouffer, G., Stys, T., Sussex, B., Tahirkheli, N., Tardif, J.-C., Gregoire, J., ten Berg, J., van Boven, A. J., von Birgelen, C., & Weinstein, D.
- Affiliations
- Baylor College of Medicine (US)
- UNSW Sydney (AU)
- Cerenis Therapeutics (France) (FR)
- Icahn School of Medicine at Mount Sinai (US)
- Montreal Heart Institute (CA)
- Amsterdam UMC Location University of Amsterdam (NL)
- Harvard University (US)
- University of California, San Francisco (US)
- University of California System (US)
- Universität Ulm (DE)
- University Hospital Zurich (CH)
- ORCID
- Ballantyne, C. M.
- Dasseux, J.-L.
- Fayad, Z. A.
- Guertin, M.-C.
- Kastelein, J. J. P.
- Paolini, J. F.
- Tawakol, A.
- Waters, D. D.
- Rouleau, J.
- Wei, L. J.
- Gosselin, G.
- Lanthier, S.
- Racine, N.
- Brilakis, E.
- Coste, P.
- Fam, N.
- Grines, C.
- Haldis, T.
- Herrman, J. P.
- Huynh, T.
- Kedhi, E.
- Koren, M.
- Kouz, S.
- Penny, W.
- Roy, A.
- Stouffer, G.
- Stys, T.
- Tahirkheli, N.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-29
- Volume
- 35
- Issue
- 46
- Pages
- 3277-3286
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC4258222
- OpenAlex
- W2126147349
- Cited by
- 251
- References
- 25
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 10 · 2023: 14 · 2022: 16 · 2021: 19 · 2020: 19 · 2019: 22 · 2018: 29 · 2017: 23 · 2016: 30 · 2015: 37 · 2014: 15
- FWCI
- 34.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Institut de Cardiologie de Montréal
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- high-density lipoprotein, coronary artery disease, acute coronary syndrome, atheroma volume, coronary artery stenosis, intravascular ultrasound, quantitative coronary angiography, lipid-lowering therapy, atherosclerosis regression, statins, ezetimibe, nicotinamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cardiovascular Agents, Coronary Artery Disease, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Phospholipids, Prospective Studies, Recombinant Proteins, Ultrasonography, Apolipoprotein A-I, Treatment Outcome, Coronary Angiography, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehu171
- The paper
- Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., L'Allier, P. L., Lesperance, J., Luscher, T. F., Paolini, J. F., Tawakol, A., Waters, D. D., for the Can Hdl Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators, Pfeffer, M., Brown, V., . . . Weinstein, D. (2014). Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
